Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

A Phase 2, Open Label, Randomized, Active-Controlled Pilot Study MW-III vs Silver Sulfadiazine Second Degree Thermal Burns

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01297400
Recruitment Status : Recruiting
First Posted : February 16, 2011
Last Update Posted : April 12, 2023
Information provided by (Responsible Party):
Skingenix, Inc.

Brief Summary:
To compare MW-III to Silvadene® Cream 1% (Silver Sulfadiazine) with respect to "time to healing" in second-degree thermal burns

Condition or disease Intervention/treatment Phase
Burns Drug: Investigational Drug, MW-III Drug: Silvadene® Cream 1% [Silver Sulfadiazine] Phase 2

Detailed Description:
This is an open-label, randomized, active-controlled pilot study to evaluate the efficacy and safety profile of topical MW-III versus an active control (Silvadene® Cream 1% [Silver Sulfadiazine]) in the treatment of second-degree thermal burns in adults. Approximately 30 subjects per treatment group will be enrolled and 60 subjects in total.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Open-Label, Randomized, Active-Controlled Pilot Study of Investigational Drug, MW-III Versus Silvadene® Cream 1% (Silver Sulfadiazine) Topically Applied to Second-Degree Thermal Burns in Adults
Actual Study Start Date : March 11, 2022
Estimated Primary Completion Date : December 22, 2023
Estimated Study Completion Date : March 22, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Burns

Arm Intervention/treatment
Experimental: Investigational Drug, MW-III
Investigational Drug, MW-III
Drug: Investigational Drug, MW-III
Topical application, twice a day

Active Comparator: Standard of care
Silvadene® Cream 1% [Silver Sulfadiazine]
Drug: Silvadene® Cream 1% [Silver Sulfadiazine]
Topical application, twice a day

Primary Outcome Measures :
  1. Time to healing, with a healed wound (wound healing) defined as ≥95% re-epithelialization of the target wound [ Time Frame: 28 days Treatment Period ]

Secondary Outcome Measures :
  1. Degree of re-epithelialization (%) at each scheduled study assessment [ Time Frame: 28 days Treatment Period and Follow-up Days 45, 60 and 90 ]
  2. Proportion of subjects determined to require excision/grafting of burn wound by Day 28 [ Time Frame: 28 days Treatment Period and Follow-up Days 45, 60 and 90 ]
  3. Scar scores at Days 28, 45, 60 and 90 [ Time Frame: 28 days Treatment Period and Follow-up Days 45, 60 and 90 ]
  4. Proportion of subjects with a healed wound by each scheduled study assessment [ Time Frame: 28 days Treatment Period and Follow-up Days 45, 60 and 90 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Adults (≥18 years of age) on the day of signing the informed consent
  2. Diagnosed with a single second-degree thermal burn
  3. Burn occurrence ≤24 hours prior to study entry
  4. Able and willing to give informed consent and comply with study procedures.

Exclusion Criteria:

  1. Patients with the co-existence of full thickness (third-degree) burn wound
  2. Multiple second-degree thermal burns
  3. Circumferential burns or burns deemed high risk for developing compartment syndrome
  4. Target burn wound requiring surgical intervention, such as excision/grafting

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01297400

Layout table for location contacts
Contact: Vicki Christodoulou, MS, JD 909-587-1650 ext 1682
Contact: Eric Wang, MD 909-587-1650 ext 1678

Layout table for location information
United States, Arizona
Valleywise Health Medical Center Recruiting
Phoenix, Arizona, United States, 85008
United States, District of Columbia
MedStar Washington Hospital Center Recruiting
Washington, District of Columbia, United States, 20010
United States, Georgia
Joseph M. Still Burn Center, Doctor's Hospital Recruiting
Augusta, Georgia, United States, 30909
United States, Louisiana
University Medical Center New Orleans Recruiting
New Orleans, Louisiana, United States, 70112
Sponsors and Collaborators
Skingenix, Inc.
Layout table for additonal information
Responsible Party: Skingenix, Inc. Identifier: NCT01297400    
Other Study ID Numbers: MW-III-BURN-2-001
First Posted: February 16, 2011    Key Record Dates
Last Update Posted: April 12, 2023
Last Verified: April 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Skingenix, Inc.:
Burns, Partial Thickness Burns
Additional relevant MeSH terms:
Layout table for MeSH terms
Wounds and Injuries
Silver Sulfadiazine
Anti-Bacterial Agents
Anti-Infective Agents
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents, Local